Radiopharm Theranostics Limited (RAD) Price & Analysis

Compare

22 Followers

RAD Stock Chart & Stats

AU$0.03

AU$0.00(0.00%)

At close: Jan 09 4:00 PM EST

AU$0.03

AU$0.00(0.00%)

Day’s Range― - ―

52-Week RangeAU$0.02 - AU$0.04

Previous CloseN/A

Volume5.13M

Average Volume (3M)4.84M

Market Cap

AU$92.15M

Enterprise ValueAU$20.99M

Total Cash (Recent Filing)AU$29.12M

Total Debt (Recent Filing)AU$0.00

Price to Earnings (P/E)―

Beta1.08

Next Earnings

Feb 26, 2026

EPS Estimate

-0.01

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.01

Shares Outstanding3,544,216,000

10 Day Avg. Volume4,365,338

30 Day Avg. Volume4,842,346

Financial Highlights & Ratios

PEG Ratio0.01

Price to Book (P/B)1.02

Price to Sales (P/S)3.42

P/FCF Ratio-1.25

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

AU$0.06

Price Target Upside100.00% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Market ExposureThe launch of American Depository Shares, with plans for a secondary listing on Nasdaq, positions Radiopharm for broader market exposure.

Partnership OpportunitiesRadiopharm's portfolio of imaging and therapeutic radiopharmaceutical agents provides the company with opportunities for medium- to long-term growth and potential non-dilutive capital via partnerships.

Therapeutic PipelineRadiopharm Theranostics has focused its therapeutic pipeline on biologically validated targets that have seen limited or no use in radiopharmaceuticals, which is designed to de-risk development and limit competition.

Bears Say

Capital RaiseThe AUD 70M capital raise resulted in higher dilution than previously estimated due to associated lower prices.

Radiopharm Theranostics Limited News

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by...

5d ago

AIM

RADX

Radiopharm price target raised to $15 from $12 at Maxim

Maxim analyst Michael Okunewitch raised the firm’s price target on Radiopharm (RADX) to $15 from $12 and keeps...

5d ago

RADX

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by...

6d ago

RADX

Radiopharm price target raised to $16 from $13 at B. Riley

B. Riley raised the firm’s price target on Radiopharm (RADX) to $16 from $13 and keeps a Buy...

6d ago

RADX

Radiopharm achieves primary endpoint in 92% of patients in RAD 101 trial

Radiopharm (RADX) Theranostics announced interim data from the first twelve patients in its U.S. Phase 2b clinical imaging...

7d ago

RADX

Radiopharm price target lowered to $13 from $15 at B. Riley

B. Riley lowered the firm’s price target on Radiopharm (RADX) to $13 from $15 and keeps a Buy...

26d ago

RADX

Radiopharm Theranostics Increases Director Paul Hopper’s Option Holdings After AGM Approval

Radiopharm Theranostics Limited ( ($AU:RAD) ) just unveiled an announcement. Radiopharm Theranostics has disclosed a change in the...

3d ago

RAD

Radiopharm Theranostics Increases Director Ian Turner’s Option Holdings After Shareholder Approval

Radiopharm Theranostics Limited ( ($AU:RAD) ) has shared an update. Radiopharm Theranostics has disclosed a change in director...

3d ago

RAD

Radiopharm Theranostics Issues 99.3 Million Unquoted Options Under Employee Incentive Scheme

An update from Radiopharm Theranostics Limited ( ($AU:RAD) ) is now available. Radiopharm Theranostics Limited has notified the...

3d ago

RAD

Radiopharm Theranostics Announces Proposed Share Placement

Radiopharm Theranostics Limited ( ($AU:RAD) ) just unveiled an announcement. Radiopharm Theranostics Limited has announced the proposed issuance...

4d ago

RAD

Radiopharm Theranostics Establishes ATM Facility to Expand U.S. Capital Fundraising Opportunities

Radiopharm Theranostics Limited ( ($AU:RAD) ) just unveiled an announcement. Radiopharm Theranostics Limited has announced the establishment of...

4d ago

RAD

Radiopharm Theranostics Addresses ASX Listing Rule Compliance Issue

Radiopharm Theranostics Limited ( ($AU:RAD) ) just unveiled an announcement. Radiopharm Theranostics Limited recently announced an inadvertent non-compliance...

4d ago

RAD

Buy Rating for Radiopharm Theranostics Limited Driven by Promising Clinical Developments and Growth Potential

Analyst Justin Walsh of JonesTrading reiterated a Buy rating on Radiopharm Theranostics Limited Sponsored ADR, retaining the price...

5d ago

RADX

Radiopharm Theranostics’ RAD 101 Achieves Key Trial Milestone in Brain Metastases

An announcement from Radiopharm Theranostics Limited ( ($AU:RAD) ) is now available. Radiopharm Theranostics announced that their Phase...

7d ago

RAD

RAD FAQ

What was Radiopharm Theranostics Limited’s price range in the past 12 months?

Radiopharm Theranostics Limited lowest share price was AU$0.02 and its highest was AU$0.04 in the past 12 months.

What is Radiopharm Theranostics Limited’s market cap?

Radiopharm Theranostics Limited’s market cap is AU$92.15M.

When is Radiopharm Theranostics Limited’s upcoming earnings report date?

Radiopharm Theranostics Limited’s upcoming earnings report date is Feb 26, 2026 which is in 66 days.

How were Radiopharm Theranostics Limited’s earnings last quarter?

Radiopharm Theranostics Limited released its earnings results on Sep 16, 2025. The company reported -AU$0.01 earnings per share for the quarter, the consensus estimate of -AU$0.01 by AU$0.

Is Radiopharm Theranostics Limited overvalued?

According to Wall Street analysts Radiopharm Theranostics Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Radiopharm Theranostics Limited pay dividends?

Radiopharm Theranostics Limited does not currently pay dividends.

What is Radiopharm Theranostics Limited’s EPS estimate?

Radiopharm Theranostics Limited’s EPS estimate is -0.01.

How many shares outstanding does Radiopharm Theranostics Limited have?

Radiopharm Theranostics Limited has 3,544,216,000 shares outstanding.

What happened to Radiopharm Theranostics Limited’s price movement after its last earnings report?

Radiopharm Theranostics Limited reported an EPS of -AU$0.01 in its last earnings report, expectations of -AU$0.01. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Radiopharm Theranostics Limited?

Currently, no hedge funds are holding shares in AU:RAD

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Radiopharm Theranostics Limited Stock Smart Score

Neutral

Fundamentals

Return on Equity

-100.67%

Trailing 12-Months

Asset Growth

20.05%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Radiopharm Theranostics Limited

Radiopharm Theranostics Limited develops radiopharmaceutical products for diagnostic and therapeutic uses. The company was incorporated in 2021 and is based in Carlton, Australia.

Radiopharm Theranostics Limited (RAD) Earnings & Revenues

Historic Earnings Reports

RAD Stock 12 Month Forecast

Average Price Target

AU$0.06

▲(100.00% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"AU$0","1":"AU$1","-1":"-AU$1","-0.5":"-AU$0.5","0.5":"AU$0.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":0.06,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">AU$0.06</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.06,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">AU$0.06</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.06,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">AU$0.06</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,-0.5,0,0.5,1],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2023","6":"Jun<br/>2024","9":"Apr<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.02,0.023076923076923078,0.026153846153846153,0.02923076923076923,0.03230769230769231,0.03538461538461538,0.038461538461538464,0.04153846153846154,0.04461538461538461,0.04769230769230769,0.05076923076923076,0.053846153846153835,0.05692307692307692,{"y":0.06,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.02,0.023076923076923078,0.026153846153846153,0.02923076923076923,0.03230769230769231,0.03538461538461538,0.038461538461538464,0.04153846153846154,0.04461538461538461,0.04769230769230769,0.05076923076923076,0.053846153846153835,0.05692307692307692,{"y":0.06,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.02,0.023076923076923078,0.026153846153846153,0.02923076923076923,0.03230769230769231,0.03538461538461538,0.038461538461538464,0.04153846153846154,0.04461538461538461,0.04769230769230769,0.05076923076923076,0.053846153846153835,0.05692307692307692,{"y":0.06,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.12,"date":1675209600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.12,"date":1677628800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.12,"date":1677628800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.15,"date":1680307200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.13,"date":1685577600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.07,"date":1704067200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.03,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.04,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.03,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.02,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.02,"date":1746057600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.03,"date":1748736000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.02,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >